Adenoviral‐induced rash and mucositis: Expanding the spectrum of reactive infectious mucocutaneous eruption

Gámez-González, Luisa Berenise; Peña-Varela, Claudia; Ramírez-López, Jesus Moises; Yamazaki‐Nakashimada, Marco Antonio

doi:10.1111/pde.14419

Cited by 15 publications

(11 citation statements)

References 5 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Canavan et al named this dermatosis Mycoplasma pneumoniae -induced rash and mucositis (MIRM) and classified it as distinct from SJS/TEN and EM. Subsequently, multiple other studies implicated other infections as causes of MIRM-like reactions including adenovirus [ 64 ], influenza B [ 65 ], and Chlamydia pneumoniae [ 66 ].…”

Section: Clinical Updatesmentioning

confidence: 99%

Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management

et al. 2021

View full text Add to dashboard Cite

Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are rare diseases that are characterized by widespread epidermal necrosis and sloughing of skin. They are associated with significant morbidity and mortality, and early diagnosis and treatment is critical in achieving favorable outcomes for patients. In this scoping review, Excerpta Medica dataBASE and PubMed were searched for publications that addressed recent advances in the diagnosis and management of the disease. Multiple proteins (galectin 7 and RIP3) were identified that are promising potential biomarkers for SJS/TEN, although both are still in early phases of research. Regarding treatment, cyclosporine is the most effective therapy for the treatment of SJS, and a combination of intravenous immunoglobulin (IVIg) and corticosteroids is most effective for SJS/TEN overlap and TEN. Due to the rare nature of the disease, there is a lack of prospective, randomized controlled trials and conducting these in the future would provide valuable insights into the management of this disease.

show abstract

Section: Clinical Updatesmentioning

confidence: 99%

Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management

et al. 2021

View full text Add to dashboard Cite

show abstract

“… 2 In recent years, other infectious etiologies such as Chlamydia pneumoniae , influenza B, adenovirus, and group A Streptococcus have been described to produce mucocutaneous eruptions indistinguishable from MIRM. 3 , 4 , 5 , 6 , 7 , 8 This has led to the term reactive infectious mucocutaneous eruption (RIME) as a reflection that other infections may stimulate this mucocutaneous eruption. Recurrent episodes are poorly understood.…”

Section: Introductionmentioning

confidence: 99%

“…MIRM is an entity distinct from erythema multiforme (EM) and Stevens‐Johnson syndrome (SJS) due to its predominance of mucosal involvement and better prognosis than the latter 2 . In recent years, other infectious etiologies such as Chlamydia pneumoniae , influenza B, adenovirus, and group A Streptococcus have been described to produce mucocutaneous eruptions indistinguishable from MIRM 3‐8 . This has led to the term reactive infectious mucocutaneous eruption (RIME) as a reflection that other infections may stimulate this mucocutaneous eruption.…”

Section: Introductionmentioning

confidence: 99%

Recurrent reactive infectious mucocutaneous eruption (RIME) in two adolescents triggered by several distinct pathogens including SARS‐CoV‐2 and influenza A

Song

Nicholson

Maguiness

2021

Pediatric Dermatology

View full text Add to dashboard Cite

Mycoplasma pneumoniae (MP) is a common cause of pneumonia that can cause mucocutaneous disease in 25%-30% of patients. 1 In 2015, Canavan introduced MIRM to describe the unique set of mucocutaneous eruptions due to MP. 2 MIRM is an entity distinct from erythema multiforme (EM) and Stevens-Johnson syndrome (SJS) due to its predominance of mucosal involvement and better prognosis than the latter. 2 In recent years, other infectious etiologies such as Chlamydia pneumoniae, influenza B, adenovirus, and group A Streptococcus have been described to produce mucocutaneous eruptions indistinguishable from MIRM. [3][4][5][6][7][8] This has led to the term reactive infectious mucocutaneous eruption (RIME) as a reflection that other infections may stimulate this mucocutaneous eruption. Recurrent episodes are poorly understood. Reports have estimated a recurrence rate ranging from 9% to 38%. 9 In this report, we describe in detail two cases of recurrent RIME with initial episodes suspected to be triggered by MP. Subsequent episodes were caused by other viral infections including SARS-CoV-2 and influenza A.

show abstract

“…RIME unifies mycoplasma-induced rash and mucositis (MIRM) and other clinically similar mucosal-predominant eruptions related to a growing number of viral infections, including COVID-19. 2 , 7 – 12 RIME presents with a prodrome of respiratory symptoms during its 2- to 3-week incubation period. Nearly one-quarter of MP pneumonia patients develop mucocutaneous disease, while RIME manifests in 7%.…”

Section: Discussionmentioning

confidence: 99%

Reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: A case report

Tonkin

Ladha

Johnson

et al. 2022

SAGE Open Medical Case Reports

View full text Add to dashboard Cite

Reactive infectious mucocutaneous eruption is a recently distinguished mucosal-predominant blistering eruption triggered by respiratory infections. We describe a previously healthy 11-year-old Black female with rapidly progressive mucocutaneous blistering after prodromal respiratory infection symptoms. Reactive infectious mucocutaneous eruption was suspected and treated with systemic corticosteroids followed by etanercept. Twenty-four hours after etanercept, the diagnosis of multisystem inflammatory syndrome in children was raised and intravenous immunoglobulin was given. Rapidly worsening mucocutaneous disease ensued but was controlled by a second dose of etanercept. Our case highlights the following: (1) the novel observation of possible interaction/neutralization of etanercept by intravenous immunoglobulin, (2) the challenging differential diagnosis of multisystem inflammatory syndrome in children for reactive infectious mucocutaneous eruption patients in the Coronavirus disease 2019 (COVID-19) pandemic, and (3) the role of early treatment to prevent dyspigmentation.

show abstract

Adenoviral‐induced rash and mucositis: Expanding the spectrum of reactive infectious mucocutaneous eruption

Cited by 15 publications

References 5 publications

Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management

Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management

Recurrent reactive infectious mucocutaneous eruption (RIME) in two adolescents triggered by several distinct pathogens including SARS‐CoV‐2 and influenza A

Reactive infectious mucocutaneous eruption – repeat etanercept after intravenous immunoglobulin: A case report

Contact Info

Product

Resources

About